|
|
|
|
|
SONGDO and RAVENSBURG, Feb 2, 2018 - (Media OutReach) - In an event at its new branch office attended by key customers and business associates, Vetter's senior management representatives presented the company's service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. In addition, attendees were introduced to Mr. Michael Yi who will manage the office in his role as Business Development Manager for Vetter Pharma International GmbH, South Korea. Mr. Yi, who is based in Songdo, has pharmaceutical experience in responsible business development roles at several companies. He reports to Ms. Chervee Ho in her role as Director Key Account Management Asia Pacific.
 | | During Vetter's customer event in the new branch office: Jong Hyun Kim, Director Supply Chain Management Department at Celltrion, Inc. (3rd from left) with Vetter's Chervee Ho, Peter Soelkner, Michael Yi and Oskar Gold (from left to right). (Picture source: Vetter Pharma International GmbH) |
A rapidly growing local economy, combined with a regulatory environment conducive to the industry is a strong incentive for doing business in the country. And, because the population is aging rapidly with corresponding needs for adequate medication, South Korea demonstrates strong commitment to the pharmaceutical market through investing and supporting campaigns in R&D that contribute to innovative healthcare products. With its branch office, Vetter is well positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.
"As a leading contract and development manufacturing organization in prefilled drug delivery systems with a vast amount of experience in business development, we are well aware that being physically close to our customers and their ongoing projects is one of the keys to good client relationships," said Vetter Managing Director Peter Soelkner. "Our event today acts as an additional signal of our strategy to build on our local presence and activities in this market," highlights Oskar Gold, Vetter's Senior Vice President Key Account Management, Marketing/Corporate Communications and Customer Project Management.
"Vetter's entry into the Korean pharmaceutical market represents an important recognition of the progress our nation has made in this segment," said Javier Camposano, Celltrion's Managing Director for Drug Product. "South Korean companies such as ours are in need of the services Vetter offers, to help us bring our innovative products to local and global markets. With its long history of qualitative resources, combined with its state-of-the art technology, Vetter can support us in competing on a level playing field and achieving our goals on a global scale. We wish Vetter a successful future in Korea."
Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center. https://www.vetter-pharma.com/en/news-events/download-center
About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. The company has long-term experience offering services ranging from early development support including clinical manufacturing, to commercial supply and various packaging solutions for vials, syringes and cartridges. Vetter's customers range from small and midsize to the world's top 20 pharmaceutical and biotech companies. As a leading solution provider, the CDMO recognizes its responsibility in supporting the needs of its customers in developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Learn more about Vetter at www.vetter-pharma.com.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com
Topic: Press release summary
Source: Vetter Pharma International GmbH
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Kincora and AngloGold Ashanti Exploration Expands and Upgrades Nevertire with Drilling Recommenced
Feb 10, 2026 19:29 HKT/SGT
|
|
|
EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong
Feb 10, 2026 18:14 HKT/SGT
|
|
|
Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season
Tuesday, February 10, 2026 5:25:00 PM
|
|
|
CTF Life+ Announces Winners of Financial Empowerment Case Competition, Innovative Platform Advances Intergenerational Inclusion
Feb 10, 2026 17:02 HKT/SGT
|
|
|
Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business
Tuesday, February 10, 2026 4:53:00 PM
|
|
|
KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Tuesday, February 10, 2026 1:15:00 PM
|
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Tuesday, February 10, 2026 12:34:00 PM
|
|
|
Spritzer EcoPark Gallops into the Year of the Horse with a Tradition-Inspired Chinese New Year Celebration
Feb 10, 2026 11:49 HKT/SGT
|
|
|
Mint Signed MoU with Robotics Leader Rice Robotics to Pioneer Physical AI Solutions Across Asia
Feb 10, 2026 09:43 HKT/SGT
|
|
|
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Monday, February 9, 2026 8:18:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
